{"slug":"api-magentlab-com-api-calc-hfa-icos-her2-85218c","title":"Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (tr","host":"api.magentlab.com","method":"POST","resource":"https://api.magentlab.com/api/calc/hfa_icos_her2","category":"other","description":"Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzumab and related agents). Very high, high, medium, or low from published factors plus Medium 1/2 points; expert-opinion cardiotoxicity guide <2% / 2-9% / 10-19% / >=20%. Concurrent anthracycline is High; sequential ","price_listed":0.005,"price_asked":0.007,"state":"overcharges","state_label":"Asked 1.4x its listed price for its own example","checks_7d":1,"answered_7d":1,"latency_ms_median":334,"reported_calls_30d":0,"reported_payers_30d":0,"networks":["eip155:8453"],"badge":"unverified","paid_checks_7d":0,"paid_ok_7d":0,"example_input":{"body":{"items":[{"age_years":50,"anthracycline_before_her2":false,"arrhythmia":false,"ckd":false,"concurrent_anthracycline_and_her2":false,"current_or_significant_smoker":false,"diabetes":false,"elevated_bnp":false,"elevated_troponin":false,"heart_failure_or_cardiomyopathy":false,"hypertension":false,"lvef_percent":60,"mi_or_cabg":false,"obesity":false,"prior_left_chest_or_mediastinal_rt":false,"prior_remote_anthracycline":false,"prior_trastuzumab_cardiotoxicity":false,"severe_valvular_heart_disease":false,"stable_angina":false},{"age_years":50,"anthracycline_before_her2":false,"arrhythmia":false,"ckd":false,"concurrent_anthracycline_and_her2":false,"current_or_significant_smoker":false,"diabetes":false,"elevated_bnp":false,"elevated_troponin":false,"heart_failure_or_cardiomyopathy":false,"hypertension":false,"lvef_percent":60,"mi_or_cabg":false,"obesity":false,"prior_left_chest_or_mediastinal_rt":false,"prior_remote_anthracycline":false,"prior_trastuzumab_cardiotoxicity":false,"severe_valvular_heart_disease":false,"stable_angina":false}]},"method":"POST","type":"http"},"output_schema":{"$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"input":{"additionalProperties":false,"properties":{"body":{"additionalProperties":false,"properties":{"items":{"items":{"properties":{"age_years":{"description":"Age in years (integer 18-100). Lyon 2020 exclusive bands: ≥80 is High; 65-79 is Medium 2 (2 points); younger than 65 does not score. Age 80 is High, not Medium 2.","type":"integer"},"anthracycline_before_her2":{"description":"Current regimen includes anthracycline before HER2-targeted therapy, sequential not concurrent (Lyon 2020 HER2 table Medium 1). true or false. Ignored for points when concurrent_anthracycline_and_her2 is true.","type":"boolean"},"arrhythmia":{"description":"Atrial fibrillation, atrial flutter, VT, or VF as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not interpret the ECG.","type":"boolean"},"ckd":{"description":"Chronic kidney disease as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false.","type":"boolean"},"concurrent_anthracycline_and_her2":{"description":"Anthracycline and trastuzumab delivered concurrently on the current protocol (Lyon 2020 HER2 table footnote f; High). true or false. When true, anthracycline_before_her2 does not add Medium 1 points.","type":"boolean"},"current_or_significant_smoker":{"description":"Current or significant smoking history as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false.","type":"boolean"},"diabetes":{"description":"Diabetes mellitus as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false.","type":"boolean"},"elevated_bnp":{"description":"Elevated BNP or NT-proBNP as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not assay natriuretic peptides.","type":"boolean"},"elevated_troponin":{"description":"Elevated troponin as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false. magent does not assay troponin.","type":"boolean"},"heart_failure_or_cardiomyopathy":{"description":"Heart failure or cardiomyopathy as assigned by the caller (Lyon 2020 HER2 table Very high). true or false.","type":"boolean"},"hypertension":{"description":"Hypertension as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false.","type":"boolean"},"lvef_percent":{"description":"Left-ventricular ejection fraction percent (integer 10-80) as assigned by the caller. <50 is High; 50-54 is Medium 2 (2 points); ≥55 does not score. magent does not measure LVEF.","type":"integer"},"mi_or_cabg":{"description":"Prior myocardial infarction or CABG as assigned by the caller (Lyon 2020 HER2 table High). true or false.","type":"boolean"},"obesity":{"description":"Obesity as assigned by the caller (Lyon 2020 HER2 table Medium 1). true or false. magent does not compute BMI.","type":"boolean"},"prior_left_chest_or_mediastinal_rt":{"description":"Prior left-chest or mediastinal radiotherapy as assigned by the caller (Lyon 2020 HER2 table Medium 2). true or false.","type":"boolean"},"prior_remote_anthracycline":{"description":"Prior remote anthracycline for a previous malignancy, not the current protocol (Lyon 2020 HER2 table footnote g; Medium 2). true or false.","type":"boolean"},"prior_trastuzumab_cardiotoxicity":{"description":"Prior trastuzumab cardiotoxicity as assigned by the caller (Lyon 2020 HER2 table Very high). true or false. magent does not review prior exposure.","type":"boolean"},"severe_valvular_heart_disease":{"description":"Severe valvular heart disease as assigned by the caller (Lyon 2020 HER2 table High). true or false.","type":"boolean"},"stable_angina":{"description":"Stable angina as assigned by the caller (Lyon 2020 HER2 table High). true or false.","type":"boolean"}},"required":["age_years","lvef_percent","heart_failure_or_cardiomyopathy","prior_trastuzumab_cardiotoxicity","mi_or_cabg","stable_angina","severe_valvular_heart_disease","concurrent_anthracycline_and_her2","arrhythmia","elevated_troponin","elevated_bnp","prior_remote_anthracycline","prior_left_chest_or_mediastinal_rt","hypertension","diabetes","ckd","anthracycline_before_her2","current_or_significant_smoker","obesity"],"type":"object"},"maxItems":25,"minItems":1,"type":"array"}},"required":["items"],"type":"object"},"headers":{"additionalProperties":{"type":"string"},"type":"object"},"method":{"const":"POST","type":"string"},"type":{"const":"http","type":"string"}},"required":["type","method"],"type":"object"},"output":{"properties":{"example":{"type":"object"},"type":{"type":"string"}},"required":["type"],"type":"object"}},"required":["input"],"type":"object"},"history":[{"day":"2026-09-28","reachable":true,"status":402,"valid_402":true,"asked_usdc":0.007,"price_match":false,"latency_ms":334,"error":null}],"description_full":"Lyon 2020 HFA-ICOS baseline cardiovascular risk before HER2-targeted therapy (trastuzumab and related agents). Very high, high, medium, or low from published factors plus Medium 1/2 points; expert-opinion cardiotoxicity guide <2% / 2-9% / 10-19% / >=20%. Concurrent anthracycline is High; sequential anthracycline before HER2 is Medium 1. Deterministic published classification with citation; not a treatment order. magent does not measure LVEF or biomarkers.","last_updated":"2026-09-28T13:45:14.972Z","schemes":["exact"]}